Montana is poised to become the first US state to serve as a hub for experimental medical treatments following the passage of a groundbreaking bill. The legislation allows clinics to sell unproven drugs and therapies that have not been approved by the Food and Drug Administration, provided they have completed phase I clinical trials. This marks the most sweeping legislation in the country to provide patients access to drugs not fully vetted for efficacy, and it has been heavily advocated for by longevity enthusiasts. Supporters hope that Montana´s new law will serve as a test bed for broader access to experimental medicines aimed at extending human lifespans.
In a separate development, Google DeepMind unveiled AlphaEvolve, a new Artificial Intelligence agent capable of solving practical problems with greater accuracy and efficiency than existing human-derived solutions. The tool leverages large language models to generate and iteratively refine code, using internal evaluation to discard ineffective solutions and enhance good ones. AlphaEvolve has demonstrated significant breakthroughs in both theoretical puzzles and critical real-world computational processes, raising the bar for Artificial Intelligence´s role in complex problem-solving beyond traditional human limitations.
Meanwhile, concerns are mounting over proposed research funding cuts that threaten essential climate data collection in the US. Programs tracking environmental metrics such as snowpack levels, CO2 concentrations, and the socioeconomic impact of natural disasters risk being downsized or eliminated. Experts warn that reduced scientific data availability could impede efforts to understand and address climate change. These major developments coincide with ongoing debates about regulatory standards for medical treatments and increasing scrutiny of Artificial Intelligence in healthcare and scientific research, driving conversations about accessibility, efficacy, and oversight in rapidly advancing technological fields.
